Sellas, Life

Sellas Life Sciences: A Phase 3 Win, a Raised Target, and the Dilution Trade-Off

Published on 11/18/2026 at 17:11 | Editorial boerse-global.de
Maxim lifted its Sellas price target to $40 from $30, citing REGAL survival data, as the company announced a $150 million stock offering.
Sellas Life Sciences Illustration mit AI erstellt.

Maxim has lifted its price target on Sellas Life Sciences from $30 to $40 while reaffirming its buy rating, according to media reports published today. The upgrade rests on the survival benefit galinpepimut-S (GPS) delivered in the Phase 3 REGAL trial — but it lands at an awkward moment, arriving just as the company moves to raise fresh capital through a stock offering and before the full study analyses have seen the light of day.

What REGAL Actually Showed

The clinical case for the higher target is the primary endpoint itself. The immunotherapeutic cancer vaccine met overall survival in REGAL, a trial enrolling 126 patients with acute myeloid leukemia in second or later remission who were not eligible for an allogeneic stem cell transplant. GPS was administered as maintenance therapy and compared against the investigator's choice of best available treatment.

The numbers are striking within that narrowly defined population. Median overall survival reached 24.0 months on GPS versus 14.7 months in the comparator arm, and Sellas put the reduction in mortality risk at 41%. The hazard ratio came in at 0.59 with a two-sided p-value of 0.035. No new safety signals emerged; side effects were mostly mild to moderate and consisted chiefly of local injection-site reactions.

Those figures apply to patients after prior salvage therapy — not to everyone with this form of leukemia. The topline readout is in hand, but it does not substitute for the full analyses still to come. Additional data on secondary endpoints are slated for presentation at a future medical conference and peer-reviewed publication.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

The Financing Overhang

Running parallel to the clinical success is the funding question. Sellas announced yesterday a public, underwritten offering of common stock worth $150.0 million, with a 30-day option granting the underwriters up to $22.5 million in additional shares. All shares on offer are to be sold by the company, with J.P. Morgan and TD Cowen serving as joint book-running managers. Closing, timing and final terms remain subject to market conditions and further conditions — the placement should not be treated as completed.

For existing shareholders, that sets a possible dilution alongside the clinical opportunity. Its scale cannot be quantified without a final issue price and share count. Today's 11% decline in the stock falls squarely within this financing phase, even as Maxim turns more optimistic on its assessment.

A Statistical Footnote Worth Watching

The bear case has a specific foothold. Only a preliminary analysis has been released so far. TechTimes reported that neither a confidence interval nor the full dataset has been published. Those gaps do not refute the reported result, but they do limit the ability to independently gauge its statistical uncertainty and reach.

According to the same report, the analysis plan was changed in 2022: the final evaluation was subsequently to take place after 80 deaths rather than the originally planned 105. The change alone proves no methodological flaw, yet it makes the rationale for the analysis plan — and the later regulatory review — important components of any assessment. Investors should neither downplay the endpoint nor equate it with an assured approval.

The Next Hurdles

Sellas has announced talks with the US Food and Drug Administration on its approval strategy. The company is preparing a BLA submission for the first half of 2027 and is pursuing an accelerated pathway. That remains a corporate goal, not a confirmed filing or a regulatory decision.

Two separate questions therefore stay decisive for investors: what additional insight the complete REGAL analyses deliver, and on what terms the share placement gets done. A confirmed survival benefit, a planned filing and open financing conditions each need to be weighed on their own. The higher price target does not resolve any of them.

Ad

Sellas Life Sciences Stock: New Analysis - 18 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70531658 |